Skip to content

Empagliflozin

Empagliflozin is a sodium-glucose cotransporter 2 inhibitor, commonly shortened to SGLT2 inhibitor. It causes the kidneys to remove more glucose in urine. The attached catalogue represents it alone and with the DPP-4 inhibitor linagliptin.

Empagliflozin Tablets

Type 2 Diabetes Mellitus, Heart Failure

10mg · 25mg

Intended to relieve elevated blood sugar to support glycaemic stability and target renal glucose clearance.

From$4.68/ tabletView

Glyxambi

Type 2 Diabetes Mellitus

10mg + 5mg

Developed to mitigate high blood sugar parameters to support cardiovascular wellness and target metabolic targets.

From$3.04/ tabletView

Key points

  • Empagliflozin is an SGLT2 inhibitor.
  • The single-ingredient record represents 10 mg and 25 mg tablets.
  • Glyxambi combines 10 mg empagliflozin with 5 mg linagliptin.
  • Ketoacidosis, dehydration and genital infections are major safety themes.

The single-ingredient record spans several roles

Empagliflozin Tablets connects with type 2 diabetes, heart failure and cardiovascular mortality reduction. Official information also includes selected chronic kidney disease outcomes.

These roles extend beyond lowering blood glucose, but eligibility and monitoring differ by condition. The catalogue strengths identify tablets, not a condition-specific regimen.

Glyxambi adds a DPP-4 inhibitor

Glyxambi combines empagliflozin with linagliptin and sits in diabetes management. Linagliptin works through incretin pathways rather than increasing urinary glucose. This second ingredient gives Glyxambi a different medicine identity from the single-ingredient record.

SGLT2 inhibitors can cause ketoacidosis even when glucose is not extremely high. Fluid loss, urinary and genital infections, kidney status and planned surgery also feature in official safety information. The linagliptin component adds its own risks, including pancreatitis and severe joint pain.

Further reading

Related articles